Sanofi, a French healthcare business, announced on Wednesday that the first research into a high-dose influenza vaccination with a COVID-19 mRNA booster had yielded good results.
Sanofi stated initial findings from a trial comparing Sanofi’s Fluzone High-Dosage Quadrivalent vaccine to Moderna’s COVID-19 mRNA experimental booster dose revealed that the vaccines had similar immunogenicity responses as well as a similar safety and tolerability profile.
“These positive results could facilitate the implementation of Northern Hemisphere influenza and COVID-19 booster vaccination campaigns, especially in this high-risk population,” said Dr. Michael Greenberg, North America Medical Head for Vaccines at Sanofi.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…